The phase II trial of the Research and Development Journal did not achieve the expected termination of Alexion's research and development program for rare kidney disease.

2020.08.03 Research and Development NEWS: Daratumumab Triple Therapy for Multiple Myeloma Phase 3 clinically reached the main endpoint; Novartis Cosentyx was approved by the European Union to treat patients with moderate to severe plaque psoriasis in ages 6-18; BioNTech partnered with Regeneration to develop a BNT111/Libtayo combination to treat melanoma... We focus on the latest developments in pharmaceutical research and development, to provide research and development personnel with timely and accurate information reference.
(click on the title, read the original version) The results of Phase II trial did not reach the expected conclusion of Alexion's end of the rare kidney disease research and development program, Alexion's research results show that due to insufficient PK/PD response, and the inhibition of alternative pathways is not complete, ALXN2040 for C3 nephropathy (C3G) actual clinical response is not ideal.
, Alexion decided to terminate the ALXN2040 for C3G research.
Daratumumab triple therapy for multiple myeloma Phase 3 clinical end days ago, Johnson and Johnson's Janssen Pharmaceuticals in collaboration with the European Myeloma Network reported the results of Phase 3 clinical study APOLLO. the
study assessed the effectiveness and safety of datumumab subsoilic dosage form combined pomalidomide and dexamethasone (Pd) alone for patients with recurrent or incurable multiple myeloma who had been treated with lenalidomide and protease inhibitors.
results showed that the study reached the main endpoint of improving the rate of non-progressable survival, and the safety of the two therapies was consistent.
Xinda anti-CD47/PD-L1 dual-specific antibody Phase I clinical completion of China's first patient drug delivery Xinda Biopharmaceuticals announced today, its potential first anti-CD47/PD-L1 dual-specific antibody Phase I clinical study completed China's first patient drug delivery.
Drug Approval Targeting TFPI Pfizer Haemophilia New Therapy was approved clinically in China for the first time today, CDE website publicity shows that Pfizer's Martacimab injection in China was approved a clinically implied license, indications for "for 12 years of age with or without inhibition of haemophilia A or haemophilia B patients routine preventive treatment to prevent bleeding attacks or reduce the frequency of bleeding attacks."
Novartis Cosentyx has been approved by the European Union for the treatment of patients with moderate to severe plaque psoriasis aged 6-18 years, and Novartis has recently announced that the European Commission has approved the anti-inflammatory drug Cosentyx for use in children and adolescents between the ages of 6 and 18 with moderate to severe plaque psoriasis.
FDA Approved Epidiolex: Treatment of Nosclerosis-Related Epilepsy Recently, GW Pharma and its U.S. subsidiary Greenwich Biosciences announced that the FDA has approved a new adaptation to the cannabinoid drug Epidiolex oral fluid preparation for the treatment of nosclerosis-related seizures in patients up to 1 year old.
the orthosis was approved through a priority review process.
FDA's accelerated approval of Monjuvi antibody therapy comes after MorphoSys and Incyte jointly announced that the FDA has accelerated its approval of Monjuvi's listing, in combination with rinseamine, a second-line treatment for adult recurrent/incurable diffuse large B-cell lymphoma patients, including DLB stem cells from low-grade lymphoma, and patients who are not suitable for self-transplantation.
IGF-1R targeted monoanti-Tepezza is robust and durable: significantly improve eye protrusion! Horizon Pharma recently released positive topline data from two clinical trials, providing increasing evidence to support Tepezza's efficacy and safety in treating thyroid eye disease.
Fosun Pharmaceutical ethylamine butanol tablets through generic consistency evaluation 3, Fosun Pharma announced that recently, the company's controlling subsidiary Shenyang Red Flag received the State Drug Administration issued on ethylamine hydrochloride tablets "drug supplement application approval notice", the drug through generic consistency evaluation.
Zhendong Pharmaceutical multiple sclerosis new drug ZD03 was approved by clinical trials Zhendong Pharmaceuticals issued a notice on the 3rd, said that the company's subsidiary Zhendong recently received the State Drug Administration's "Drug Clinical Trial Approval Notice", ZD03 new drugs have been clinically approved.
Research and Development Partnership BioNTech and Regenerative Meta Develop BNT111/Libtayo Combination Therapy for Melanoma Recently, BioNTech announced a strategic partnership with Regenerative Meta to conduct a clinical trial of a combination of mRNA immunotherapy BNT111 FixVac and anti-PD-1 therapy Libtayo to treat melanoma.
.